AMA House of Delegates Adopts ASCO Resolutions on Step Therapy, Medicare Part B
The American Medical Association’s (AMA) House of Delegates (HOD) adopted and reaffirmed ASCO-led resolutions on cancer policy priorities, including step therapy, Medicare Part B drugs, a Competitive Acquisition Program (CAP), and clinical trial access during the recent Interim Meeting of the AMA HOD. Read more on ASCO in Action.
The Trump Administration unveiled a sweeping proposal to overhaul Medicare Part B payment as part of efforts to address the high and unsustainable prices of prescription drugs in the U.S. The proposal would set Part B payments based on the discounts manufacturers offer in other countries. Participation would cover 50 percent of the country and be mandatory in randomized geographic regions.
Two Cancer Research Organizations Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation
On August 8, 2018
ASCO and Friends of Cancer Research (Friends) submitted to the Food and Drug Administration (FDA) recommended language for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age requirements for trial enrollment, HIV/AIDS status, brain metastases, organ dysfunction, and prior and concurrent malignancies.
Oncology Practice Conference in September—Register by August 22
The conference is designed to address challenges that oncology practices face by discussing best practices and strategies to deliver high-quality, cost-effective care. As OPC Planning Committee Chair Robin Zon, MD, FACP, FASCO, who opened last year’s conference, stated, “Oncology practices face many challenges in the current dynamic environment. The goal of the ASCO Oncology Practice Conference is to address these issues by sharing best practices and strategies to preserve the delivery of high-quality, cost-effective care.”Read More
When a patient’s health insurance plan denies your request for prior authorization (PA) or coverage for a medication, you may submit an appeal. When submitting an appeal to a patient’s health insurance plan, including an Appeal Letter can help explain the rationale and clinical decision-making behind the choice of a speciﬁc therapy.
This guide will assist you in composing an Appeal Letter for your patients who have been prescribed a Genentech medicine. You can also access this guide, as well as any enclosures necessary for completing an Appeal Letter, in the Forms and Documents section of Genentech-Access.com.
Apply for ASCO’s Health Policy Leadership Development Program
Applications are now open for the 2019-2020 ASCO Health Policy Leadership Development Program (HP-LDP). Formerly the Health Policy Fellowship Program, the HP-LDP is a one-year program that provides an opportunity for ASCO members to develop expertise in health policy, advocacy, and grassroots activity.
The HP-LDP is open to all ASCO members in the United States who completed their final subspecialty training between 2009 and 2014.
Click here for more.